newsfilter
← Latest News
Business Wire·

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically